Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer
Phase 2 pilot INNOVATE data will be presented at the
Progression free survival of patients treated with Tumor Treating Fields plus weekly paclitaxel was more than double that of weekly paclitaxel-treated historical controls
ST. HELIER, Jersey–(BUSINESS WIRE)–
The INNOVATE trial was a prospective, single-arm study testing the feasibility, safety and preliminary efficacy of Tumor Treating Fields (TTFields) combined with weekly paclitaxel in recurrent ovarian cancer. Thirty-one patients with recurrent platinum-resistant ovarian cancer patients were enrolled.
Median progression free survival in the TTFields-treated group was 8.9 months (compared to 3.9 months in paclitaxel alone historical controls) and median overall survival was not yet reached. Median one-year survival was 61 percent. The median compliance of patients with TTFields in the first 3 months was 77 percent. Two cases of severe skin irritation due to TTFields were reported. No other serious device-related adverse events were reported.
“A clear unmet need remains for patients with recurrent ovarian cancer, particularly in the platinum-resistant population, with median overall survival of only 13 to 14 months post recurrence,” said Dr. Igance Vergote, Chair of the
“These are encouraging results in a disease state that is very difficult to treat and we are now working to develop a phase 3 pivotal trial protocol to further study TTFields for the treatment of recurrent ovarian cancer,” said Dr.
TTFields are not approved for the treatment of ovarian cancer by the
About Ovarian Cancer
Ovarian cancer is the fifth most common cause of cancer death in women in
Headquartered in Jersey,
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing
Media and Investor Contact:
Ashley Cordova, 212-767-7558